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Abstract: The discovery of human retroviruses in the early 1980s revealed the existence of 
viral-encoded non-structural genes that were not evident in previously described animal 
retroviruses. Based on the absence or presence of these additional genes retroviruses were 
classified as ‘simple’ and ‘complex’, respectively. Expression of most of these extra genes 
is achieved through the generation of alternatively spliced mRNAs. The present review 
summarizes  the  genetic  organization  and  expression  strategies  of  human  complex 
retroviruses and highlights the converging mechanisms controlling their life cycles. 
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1. Introduction  
Retroviruses are distinguished by a replication cycle that relies on reverse transcription of an RNA 
genome and integration of the resulting double-stranded DNA provirus into the genome of the host; 
expression of the integrated provirus gives rise to new RNA genomes and mRNAs that are translated 
into structural proteins and enzymes necessary for assembly of new virions. All retroviruses contain 
the gag, pro, pol and env genes coding for virion structural proteins and enzymes necessary for protein 
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processing, reverse transcription and integration. All these genes are coded on the plus-strand of the 
proviral genome. The Gag, Pro and Pol open reading frames (ORFs), coded in the unspliced primary 
transcript,  are  partially  overlapping  and  rely  on  one  or  two  ribosomal  frameshifting  events  for 
translation, while Env is produced from a separate singly spliced mRNA. Other conserved elements 
include long terminal repeats (LTRs) which direct transcription, polyadenylation and integration, a 
packaging signal that permits incorporation of the RNA genome into virions, and a primer binding site 
and polypurine tract that are needed for synthesis of the minus and plus strands of the provirus [1]. 
The  discovery  of  the  human  T-cell  leukemia  viruses  (HTLVs)  and  human  immunodeficiency 
viruses (HIVs) in the early 1980s revealed the existence of additional viral-encoded non-structural 
genes and regulatory elements that were not evident in previously described animal retroviruses. Based 
on  the  absence  or  presence  of  these  additional  genes  retroviruses  were  classified  as  ‘simple’  
and  ‘complex’,  respectively  [2].  Complex  retroviruses  comprise  the  Lentivirus,  Deltaretrovirus, 
Epsilonretrovirus,  and  Spumavirus  genera.  Although  Betaretroviruses  were  long  considered  to  be 
simple, the presence of extra genes and virus-directed post-transcriptional regulatory mechanisms in 
the  Betaretroviruses  mouse  murine  leukemia  virus  (MMTV)  [3,4]  and  HERV-K  family  of  human 
endogenous retroviruses [5] indicates a need to update this classification. 
For the most part, the extra genes of complex retroviruses are coded on the plus-strand of the 
provirus, with transcription from the 5′LTR promoter producing a primary transcript that undergoes 
alternative splicing. Further layers of complexity can be found in foamy viruses, which possess an 
alternative plus-strand promoter, and in HTLV and HIV, which produce minus-strand transcripts from 
promoters in the 3′LTR. Among the extra gene products that define complex retroviruses, HIV Tat and 
Rev  and  their  orthologs  in  other  complex  retroviruses  stand  out  as  key  regulatory  proteins  that 
orchestrate viral gene expression.  
Common to the expression strategies of all retroviruses is the necessity to export and translate a 
proportion of incompletely spliced mRNAs; this requires both a relative inefficiency of viral mRNA 
splicing  and  the  evasion  of  cellular  mechanisms  mediating  nuclear  retention  and  degradation  of  
intron-containing  transcripts.  For  some  simple  retroviruses  such  as  Mason-Pfizer  Monkey  virus 
(MPMV),  this  is  accomplished  through  the  interaction  of  a  cis-acting  RNA  element  termed  the 
constitutive  transport  element  (CTE)  with  the  cellular  nuclear  export  factors  NXF1/NXT1  [6]. As 
described  in  greater  detail  below,  most  of  the  complex  retroviruses  code  for  both  a  cis-acting 
regulatory element(s) and post-transcriptional regulatory proteins, whose binding to distinct stem-loop 
elements present in the viral mRNAs forms a bridge that allows interaction of the RNA with cellular 
factors mediating nucleo-cytoplasmic export. 
The patterns of alternatively spliced, plus and minus-strand mRNAs and production of essential 
regulatory proteins suggest a temporal regulation of viral expression and the possibility that different 
expression  patterns  may  be  associated  with  different  infection  states  and  disease  outcomes.  Such 
temporal regulation of viral expression has been thoroughly characterized in DNA tumor viruses such 
as  herpesviruses,  where  different  patterns  of  viral  gene  expression  are  associated  with  latent  or 
productive phases of the viral life cycle and with different diseases (reviewed in [7]). In the case of 
Epstein-Barr virus (EBV), the switch between early and late viral genes is achieved mainly through the 
genetic  and  epigenetic  regulation  of  alternative  viral  promoters.  Human  papillomaviruses  (HPV) 
exploit a combination of alternative promoter usage, alternative splicing and selection of “early” vs. Viruses 2011, 3                                       
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“late” polyadenylation sites (reviewed in [8]). The early/late pattern of HPV expression is associated 
with tissue tropism and restriction of the lytic cycle to differentiated epithelia (reviewed in [9]). 
In the present review, the lentivirus HIV-1 and the deltaretrovirus HTLV-1 are used as points of 
reference to compare the expression strategies of complex retroviruses in terms of transcript profiles, 
roles of regulatory proteins and temporal control of transcript expression. 
2. Expression Strategies of HIV-1 
Early  studies  of  HIV-1,  the  causative  agent  of  acquired  immunodeficiency  syndrome  (AIDS), 
revealed 3 classes of viral transcripts visible by northern blotting: (i) “full length” unspliced mRNA of 
about 9 kb; (ii) “intermediate” mRNAs of about 4 kb that included the singly-spliced env transcript; 
(iii) and “small” mRNAs of about 2 kb comprising several multiply spliced species [10]. Subsequent 
RT-PCR-based methods aimed at identifying transcripts coding for the virus’s 6 extra proteins (Tat, 
Rev, Nef, Vif, Vpr, and Vpu) revealed the production of over 40 alternatively-spliced plus-strand 
mRNAs with partially overlapping coding potentials [11,12]. The 4 kb class of viral mRNAs consists 
of at least 12 differentially spliced species―nine are bicistronic mRNAs producing Env and Vpu and 
three  mRNAs  express  a  1-exon  isoform  of  Tat  [13,14].  The  fact  that  Env  and  Vpu  proteins  are 
expressed from the same Rev-dependent mRNAs suggests a coordinate expression of these proteins; a 
distinct set of intermediate size, Rev-dependent mRNAs encode Vif and Vpr [13,14]. Purcell and 
Martin described an even more complex pattern of alternatively spliced mRNAs, with 12 mRNAs 
encoding Rev, 5 transcripts encoding Nef, 8 encoding Tat and 16 encoding Env [11]. In addition, 
transcription of the minus strand of HIV gives rise to a transcript that was detected in chronically-
infected cell lines and in PBMCs of HIV-infected patients; this mRNA contains an ORF with the 
potential to code for a hydrophobic protein termed ASP [15].  
Optimal expression of the alternatively spliced HIV mRNAs results from the concerted action of 
cis-acting RNA elements and trans-acting viral/cellular proteins. The former include several exonic 
splicing enhancers (ESE) and silencers (ESS) which play a crucial role in determining the “strength” 
and probability of selection of 5'splice site (SS) and 3'SS pairs resulting in exon definition. The relative 
abundance of the different HIV mRNAs is strictly dependent on their consensus sequence and on their 
regulation by ESE and ESS which exert their functions by binding cellular proteins of the SR and 
hRNP-A/B families [16,17].  
Positive regulators of viral gene expression. Balanced expression of the 3 size classes of mRNAs is 
achieved through the concerted action of the two essential viral regulatory proteins, Tat and Rev. Tat 
drives transcription from the viral LTR promoter by binding to a stem-loop RNA sequence present at 
the 5' end of all viral transcripts. This interaction results in hyperphosphorylation of the C-terminal tail 
of RNA polymerase II resulting in enhanced transcriptional elongation; through this mechanism Tat 
provides a positive-feedback loop controlling overall HIV expression [18]. The minus-strand promoter 
is also responsive to Tat transactivation, although to a lesser extent than the plus-strand promoter [19]. 
Recent  evidence  suggests  that  Tat  also  influences  HIV  expression  at  the  level  of  splicing.  In 
particular,  Berro  et  al.  showed  that  acetylated  Tat  binds  to  the  p32  cellular  protein,  resulting  in 
inhibition the activating phosphorylation of the SF2 splicing factor by the CDK13 kinase [20,21]. Viruses 2011, 3                                       
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Through this function, Tat would thus play a role in HIV expression by maintaining viral splicing 
efficiency at a low level, a key feature that is required for the function of Rev [22].  
Rev interacts with an RNA element termed the Rev-responsive element (RRE) located in the env 
region of the genome. Engagement of viral transcripts by Rev permits their exit from the nucleus by 
the export factor CRM1, thus subtracting them from the splicing machinery, which would otherwise 
result in removal of the RRE (Figure 1A). Rev-dependent mRNAs include the unspliced transcript 
which serves as the RNA genome and codes for the Gag-Pro-Pol proteins, and the series of singly 
spliced mRNAs coding for Vif, Vpr, Vpu, and Env proteins (reviewed in [23]). The RRE is spliced out 
of the multiply-spliced Rev-independent transcripts; these mRNAs include those producing Tat, Nef 
and Rev itself. In addition to affecting RNA export, Rev promotes loading of the responsive mRNAs 
onto polysomes and enhances encapsidation of the genomic RNA [24]. 
Inhibitory  elements.  Cis-acting  sequences  that  negatively  affect  transcript  expression  have  been 
mapped to the HIV-1  gag, pol and  env  genes (Figure 1A) [25–27]. Maldarelli et al. showed that  
2 inhibitory sequences present in the gag and pol regions mediate nuclear retention of the mRNAs [26]. 
Schwartz  et  al.  mapped  distinct  elements  in  the  gag-protease  genes  that  act  by  decreasing  RNA 
stability  [28];  this  inhibitory  effect  is  counteracted  by  the  Rev-RRE  interaction,  which  promotes 
nuclear export of the mRNAs [29]. These sequences, which, like the RRE, are absent in the multiply 
spliced, Rev-independent mRNAs, do not contain splice sites nor appear to act on splicing, but are rich 
in AU nucleotides, a feature that is common to cellular transcripts with short half-lives. Mutation of 
these  AU-rich  sequences  results  in  Rev-independent  gag  expression  [30].  Using  laser-scanning 
confocal  microscopy,  Berthold  and  Maldarellli  showed  that,  in  the  absence  of  Rev,  cis-acting 
inhibitory elements present in the gag gene direct viral transcripts to small nuclear granules, while viral 
transcripts  lacking  these  sequences  (i.e.,  multiply  spliced  mRNAs)  are  localized  in  distinct  large 
nuclear clusters containing the SC35 splicing factor [31]. It is not known whether these properties are 
shared  by  the  cis-acting  inhibitory  sequences  identified  in  the  env  gene,  although  their  inhibitory 
function is not attributable to the presence of splice sites [25,27]. 
Kinetics of gene expression. Early studies suggested that Rev function provides a molecular switch 
between latent and productive infection. Using a single-cycle infection model in the CD4+ T-cell line 
H9, Kim et al. showed a Rev-dependent temporal pattern in the expression of the different classes of 
HIV transcripts, with the 2-kilobase multiply-spliced mRNA group (encoding Tat, Rev, Nef) expressed 
earliest. The 9-kb and, to a lesser extent, the 4-kb classes of transcripts were detected with a delay of 
about 12 hours [32]. Consistent with these findings, Ahmad et al. showed that a Rev-mutant virus was 
replication-deficient  and  exhibited  an  expression  pattern  characterized  by  the  accumulation  of 
Nef [33]. Taken together, these studies strongly suggest that the HIV-1 life cycle is characterized by a 
two-phase kinetics with Tat, Rev, and Nef expressed as early genes and Env, Vpu, Vif, Vpr, Gag, Pro, 
and Pol expressed as late genes.  
In addition to helping dissect the mechanisms of viral gene expression, these studies provided clues 
to the mechanisms controlling viral latency, a key strategy employed by many viruses to establish  
life-long persistence in the host. Although viral expression is not completely silenced during the early Viruses 2011, 3                                       
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phase, it can be considered a form of viral latency, since the proteins and genomic RNA forming 
infectious virions cannot be produced. Prolonged viral latency may result from a blockade of this 
switch, i.e., through an inhibition of Rev function. More recent studies indicate that modulation of Tat 
activity (e.g., through acetylation) may also play a key role in determining HIV latency, resulting in a 
substantial decrease in overall viral expression [34–36]. 
The timing and relative expression of the different viral genes in relation to the host cell and clinical 
status of the patient is of particular relevance in light of the diverse functions of the regulatory and 
accessory  genes,  which  play  an  essential  role  in  controlling  viral  expression  and  in  counteracting 
antiviral  host  restriction  factors  and  circumventing  innate  and  adaptive  immune  responses,  thus 
favouring viral persistence and spread [37,38].  
Nef,  which  is  expressed  as  an  early  Rev-independent  gene,  plays  an  important  role  in  HIV 
pathogenesis, as demonstrated by the long-term survival of patients infected with Nef-defective HIV 
strains [39]. Nef enhances the clathrin-mediated endocytosis and degradation of CD4, the primary 
receptor for HIV entry [40]. Vpu, whose expression is Rev-dependent and tied to that of Env, also 
interacts with CD4, resulting in its retention in the endoplasmic reticulum (ER), polyubiquitylation and 
proteasomal degradation. The fact that two viral proteins—Nef and Vpu—target CD4 for degradation 
suggests the importance of CD4 downregulation for viral propagation, possibly at the levels of nascent 
virus assembly and release [41,42]. Vpu also promotes release of nascent virions by inhibiting tetherin, 
a surface  glycoprotein that forms  connections between the plasma membrane and virion envelope 
which hamper release of viral particles from infected cells [43].  
Nef also sabotages the host’s antiviral defenses by downregulating surface expression of MHC class 
I and T cell receptor (TCR)-CD3 complexes, the former resulting in impaired recognition of infected 
cells by CTLs (cytotoxic T-lymphocytes) and the latter reducing the efficiency of “immunological 
synapse” formation between infected cells and antigen-presenting cells [44]. The Vif protein also plays 
a key role in curbing antiviral host defenses by directing proteasomal degradation of APOBEC3G 
(apolipoprotein  B  mRNA-editing  enzyme  catalytic  polypeptide-like  3G),  an  enzyme  that  induces 
hypermutation of the viral genome by deaminating C residues in the nascent minus-strand product of 
reverse transcription [45]. Vpr exerts cytopathic effects mediated by its ability to affect mitochondrial 
function, increases viral transcription and induces cell-cycle arrest in the G2 phase [37]. Vpr is also 
incorporated into viral particles and facilitates transport of the preintegration complex into the nucleus, 
a function that was proposed to be particularly relevant in infection and persistence in non-dividing 
cells such as macrophages [46] (Table 1). 
In analogy to HIV, animal lentiviruses such as OMVV (ovine maedi-visna virus), CAEV (caprine 
arthritis encephalitis virus) and EIAV (equine infectious anemia virus) also express several multiply 
spliced mRNAs encoding regulatory proteins, with balanced transcript expression controlled by Rev 
orthologs  and  cognate  Rev-responsive  elements  (RRE).  Schoborg  et  al.  [47]  demonstrated  a 
“two-phase” temporal pattern of viral gene expression in CAEV-infected cells, with Rev expressed as 
an early gene and Gag expressed as a late gene. These data are consistent with findings from studies of 
OMVV-infected sheep cells, where expression of small multiply-spliced transcripts (encoding Rev and 
Tat orthologs) precedes that of transcripts encoding Gag and Env [48]. In the case of EIAV, although 
the function of EIAV-Rev is analogous to that of HIV-1 Rev, there are significant differences in the 
cis- and trans-acting components [49]. Martarano et al. [49] demonstrated that, in the absence of EIAV Viruses 2011, 3                                       
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Rev, the mRNA containing exons 1-2-3-4, encoding both Tat and Rev, is predominant, while in the 
presence of Rev, exon 3 is skipped and the resulting mRNA 1-2-4 produces Tat. 
Figure  1.  Exon  composition  and  coding  potential  of  the  main  plus-strand  mRNAs  of 
HIV-1 (reviewed in [16]) (A) and HTLV-1 (B). The INhibitory Sequences (INS) and the 
Rev/Rex-Responsive  Element  (RRE/RXRE)  are  indicated  by  red  hexagons  and  green 
boxes, respectively.  
 
 
Table 1. Functional characteristics of human immunodeficiency virus-1 (HIV-1) accessory proteins. 
PROTEIN  LOCALIZATION  FUNCTION 
Nef  cytoplasm, nucleus, 
virion 
enhances clathrin-mediated endocytosis and degradation of 
CD4; downregulates surface expression of MHC class I and T 
cell receptor (TCR)-CD3 complexes 
Vpu  cytoplasm, nucleus 
favors CD4 retention in the endoplasmic reticulum and 
proteasomal degradation; promotes release of nascent virions 
from infected cells by inhibiting tetherin 
Vif  cytoplasm, virion  induces proteasomal degradation of the APOBEC3G restriction 
factor 
Vpr  nucleus 
mitochondria, virion 
exerts cytopathic effects through its ability to affect 
mitochondrial function; increases viral transcription and induces 
cell-cycle arrest in the G2 phase Viruses 2011, 3                                       
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3. Expression Strategies of HTLV-1 
HTLV-1  is  the  causative  agent  of  adult  T-cell  leukemia/lymphoma  (ATLL),  an  aggressive 
malignancy  of  mature  CD4+  T-cells,  and  of  tropical  spastic  paraparesis/HTLV-1-associated 
myelopathy  (TSP/HAM),  a  demyelinating  neurodegenerative  disease.  HTLV-1  exhibits  a  complex 
genetic  organization  and  expression  strategy  characterized  by  the  production  of  several  additional 
regulatory and accessory genes located at the 3′ end of the genome (the pX region), characteristics that 
are  shared  with  the  other  deltaretroviruses  (HTLV-2,  STLVs  and  BLV).  The  pX  region  of  
HTLV-1 contains four major overlapping ORFs, termed x-I through x-IV, coding for the regulatory 
proteins Tax and Rex and the accessory proteins p12, p13, p30/Tof and p21Rex [50,51]. The minus 
strand of HTLV-1 also contains an ORF located in the pX region [52] which codes for the HBZ 
protein (HTLV-1 bZIP factor) [53]. 
As in HIV, expression of the highly condensed genetic information of HTLV-1 is achieved through 
ribosomal frameshifting (which generates a Gag-Pro-Pol polyprotein from the full-length transcript), 
polycistronic  translation  (which  directs  production  of  Tax  and  Rex  from  the  same  mRNA)  and 
alternative  splicing.  Minus-strand  transcription  generates  at  least  2  alternatively  spliced  transcripts 
coding for 2 isoforms of the HBZ protein [52,53]. The HTLV-1 transcripts can be grouped in 4 major 
classes: (a) genomic unspliced mRNA, coding for Gag-Pro-Pol; (b) singly-spliced mRNAs, coding for 
the Envelope glycoproteins and for the accessory proteins p21Rex, p12 and p13; (c) doubly-spliced 
mRNAs, coding for the regulatory proteins p40 (Tax) and p27 (Rex), and for the regulatory/accessory 
protein p30Tof; (d) mRNAs generated from minus strand transcription, coding for HBZ. 
Positive  regulators  of  viral  gene  expression.  HTLV-1  expression  is  controlled  by  two  regulatory 
circuits: a positive feedback loop provided by the viral transactivator Tax that drives transcription of 
the viral genome [54], and a post-transcriptional regulatory loop provided by Rex which, by binding to 
the  Rex-responsive  element  (RXRE)  present  at  the  3'  end  of  all  plus-strand  HTLV-1  transcripts, 
enhances the nuclear export and expression of a subset of mRNAs [55,56]. In analogy to HIV-1 Rev, 
the effect of Rex on the nucleo-cytoplasmic export of viral mRNAs is mediated through binding to 
CRM1 [57]. Interestingly, while HTLV-1 Rex can also function on the RRE of HIV-1, HIV-1 Rev is 
unable to act on the HTLV-I RXRE [58]. 
Inhibitory elements. As in the case of HIV, negative cis-acting inhibitory elements (INS) within the 
gag-pol and env regions of HTLV-1 (Figure 1B) are at least in part responsible for the Rex dependence 
of the full-length mRNA and the singly spliced env mRNAs [59]. This inhibitory effect is not affected 
by Tax, but is relieved by binding of Rex to the RXRE, suggesting that the INS act at the RNA level. 
Kinetics of gene expression. The study of the kinetics of viral expression in HTLV-1 is difficult due to 
its relative inefficiency  in infecting target cells in “cell-free” in vitro systems. This limitation has 
prevented the use of single-cycle infection systems employed for HIV-1. The first study aimed at 
investigating  the  kinetics  and  regulation  of  HTLV-1  gene  expression  was  based  on  the  transient 
transfection  of  an  HTLV-1  molecular  clone  followed  by  Northern  blotting  of  the  polyadenylated, 
cytoplasmic mRNA fraction [55]. Results revealed three bands of 8.5, 4.2 and 2.1 kb, corresponding to 
unspliced, singly-spliced and doubly-spliced transcripts, respectively. Interestingly, only the 2.1-kb Viruses 2011, 3                                       
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mRNA was detected early after transfection (10 hours), while the 8.5-kb and 4.2-kb mRNAs were 
detected at 16 hours. At later time points expression of the 8.5-kb and 4.2-kb bands increased while the 
2.1-kb  band  decreased  slightly.  Fifty-two  hours  after  transfection  the  2.1-kb  mRNA  was  barely 
detectable,  while  the  8.5-kb  and  4.1-kb  mRNAs  were  still  detected.  Based  on  these  findings,  the 
investigators indicated three stages of HTLV-1 expression: “early”, in which only the 2.1-kb mRNA is 
present; “intermediate”, in which all three classes of viral mRNAs are present; “late” in which only the 
8.5-kb and 4.2-kb transcripts are detected. In cells transfected with a Rex-mutant molecular clone, only 
the 2.1-kb mRNA was detectable 40 hours after transfection, demonstrating that Rex is essential for 
accumulation of the 8.5-kb and 4.2-kb mRNAs.  
Although  these  early  studies  showed  a  qualitative  switch  among  classes  of  HTLV-1  mRNAs 
(multiply-spliced  vs.  unspliced/singly-spliced  mRNAs),  the  detection  of  a  temporal  switch  in  the 
expression  of  individual  viral  transcripts  proved  difficult  to  demonstrate  experimentally  using 
quantitative transcript-specific Real Time RT-PCR [60,61]. A study performed using PBMCs obtained 
from  HTLV-1-inoculated  rabbits  indicated  early  expression  of  gag/pol,  tax/rex  and  env  mRNAs, 
whereas the accessory genes and the antisense HBZ mRNAs were expressed late [61]. Such early 
expression of gag/pol and env mRNAs was unexpected considering earlier results based on Northern 
blotting [55]. Analysis of the kinetics of HTLV-1 gene expression in the rabbits indicated that the 
tax/rex  and  gag/pol  mRNAs  were  expressed  very  early  after  inoculation  and  then  progressively 
decreased, while the HBZ mRNA was present at low levels at early time points and slowly increased 
and stabilized over time in direct correlation with the proviral load [61]. 
We recently investigated the temporal sequence of HTLV-1 gene expression using splice site-specific 
Real Time RT-PCR in an ex vivo virus reactivation model based on the depletion of CD8+ T cells from 
unstimulated  PBMCs  isolated  from  HTLV-1-infected  patients  (ATLL  and  TSP/HAM)  [62].  The 
results  indicated  a  “two-phase”  kinetics  with  tax/rex  expression  preceding  that  of  all  other  viral 
transcripts, suggesting an “early-late” switch in HTLV-1 gene expression. Analysis of cells transfected 
with HTLV-1 molecular clones demonstrated the strict Rex-dependency of this “two-phase” kinetics. 
Mathematical modeling indicated that the observed two-phase kinetics must be critically dependent on 
a  delay  of  Rex  function  compared  to  Tax  [63].  This  prediction  was  supported  by  experimental 
evidence demonstrating a delayed accumulation and a longer half-life of Rex compared to Tax [62]. 
The expansion and survival of HTLV-1-infected T-cells can be attributed primarily to Tax, whose 
activity as a modulator of a variety of transcription factors and associations with components of signal 
transduction pathways alter expression of host-cell genes involved in proliferation, genetic stability, 
and apoptosis (reviewed by [64–66]). The other X region genes also exhibit interesting (and in some 
cases opposite) effects on viral replication, infected-cell turnover and persistence in the host (Table 2). 
Changes  in  the  relative  abundance  and  timing  of  expression  of  these  genes  may  therefore  have 
important effects on the outcome of infection. Viruses 2011, 3                                       
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Table 2. Functional characteristics of HTLV-1 accessory proteins. 
PROTEIN  LOCALIZATION  FUNCTION 
p30Tof  nucleolus, nucleus 
inhibits nuclear export of the tax/rex mRNA; affects 
Tax-mediated transcription; affects the expression of 
cellular genes; interacts with Rex; interferes with 
TLR4 signaling 
p21Rex  cytoplasm  represses Rex in some experimental systems 
p13 
mitochondrial inner 
membrane, nucleus 
alters mitochondrial K
+ permeability and increases 
mitochondrial ROS production; activates normal 
resting T-cells while promoting death of transformed 
cells; exerts antitumor effects in vivo; inhibits Tax 
function in the nucleus 
p12 
endoplasmic reticulum, Golgi 
apparatus 
binds to the IL-2R β and γ chains; sequesters free 
MHC-I heavy chains;  
interacts with calreticulin and calnexin resulting in 
Ca
2+ release from the ER and NFAT activation 
p8 
cell surface, immunological 
synapse 
recruited to the immunological synapse; 
increases T-cell contacts through LFA1 and 
intercellular conduits 
HBZ  nucleus 
HBZ protein: inhibits Tax, Jun-B and c-Jun; stimulates 
Jun-D; 
HBZ RNA: growth-promoting effects in T-cells 
 
p30Tof  is  a  nucleolar/nuclear  non-shuttling  protein  [67]  that  inhibits  the  nuclear  export  of  the 
tax/rex mRNA; this effect results in a global inhibition of viral gene expression, suggesting that it 
might act as a latency factor [68,69]. p30Tof also affects Tax-mediated transcription by interacting 
with the co-activator CBP/p300 [70,71] and influences the expression of a number of cellular genes at 
the transcriptional and post-transcriptional levels, including genes involved in T-cell activation and 
apoptosis [72,73]. In addition, p30Tof was found to interact with the RNA-binding domain of Rex and 
prevent  Rex  interacting  with  the  RxRE  [74].  p30Tof  also  interacts  with  PU.1  and  inhibits  its 
transcriptional activity, resulting in the down-regulation of Toll-like receptor 4 (TLR4) expression 
from the cell surface [75]. 
Another HTLV-1 protein that is proposed to act as a latency-inducing factor is p21Rex, a truncated 
isoform of Rex lacking the N-terminal RNA-binding and multimerization domains of the full-length 
protein. p21Rex was proposed to act as a repressor of full-length Rex [76,77], resulting in a reduction 
in the expression of the transcripts coding for the structural viral proteins. 
p13,  an  87-amino  acid  protein  that  corresponds  to  the  C-terminal  portion  of  p30Tof  [51], 
accumulates  in  the  mitochondrial  inner  membrane  [78]  and  induces  alterations  in  mitochondrial 
function [78,79], cell turnover [80,81] and tumor growth in in vivo experimental models [80]. Recent 
studies suggest that by controlling mitochondrial ROS production, p13 may have a distinct impact on 
cell  survival  and  proliferation  depending  on  the  cell’s  inherent  ROS  set-point,  with  activation 
predominating in normal resting T-cells and death-promoting effects in transformed cells [82,83]. In Viruses 2011, 3                                       
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the presence of Tax, p13 is stabilized and partially targeted to the nucleus, where it binds Tax and 
inhibits its transcriptional activity [83,84]. 
p12 accumulates in the ER and Golgi apparatus, where it
 interacts with the β and γc chains of the 
interleukin-2 receptor (IL-2R), resulting in reduced surface expression [85] and an increase in the 
transcriptional activity of STAT-5, thereby providing a proliferative advantage to T cells [86]. p12 also 
decreases  surface  expression  of  MHC-I,  thus  contributing  to  blunt  CTL  recognition  of  HTLV-1 
infected  cells  [87].  These  effects  on  the  surface  expression  of  key  T-cell  signaling  molecules  are 
reminiscent of HIV Nef (see above). p12 also interacts with calreticulin and calnexin [88], resulting in 
Ca
2+ leakage from the ER [89] and NFAT activation [90,91]; taken together, these effects decrease the 
activation threshold of HTLV-1-infected T-cells [92]. Proteolytic cleavage of p12 in the ER yields an 
8-kDa  protein  named  p8  which  traffics  to  the  cell  surface  and  is  recruited  to  the  immunological 
synapse, resulting in promotion of T-cell anergy; it also triggers the formation of conduits among 
neighboring T-cells, resulting in increased virus transmission [93,94]. This latter function of p8 is 
reminiscent of “long-range intercellular nanotubes” induced by HIV Nef [95]. Although HIV-1 and 
HTLV-1 have clearly distinct pathogenic properties, the functional analogies among their regulatory 
and accessory proteins highlight common strategies that these viruses must have evolved for life-long 
persistence in the host. 
The HBZ protein interacts with a number of transcription factors, including CREB-2, p300/CBP, 
Jun  family  members,  and  NF-κB  [96].  HBZ  inhibits  Tax-mediated  viral  transcription  [53,97]  and 
promotes proliferation of ATLL cells in vivo and in vitro [98,99]. The hbz mRNA has a growth-
promoting effect on T-cells [99] possibly by up-regulating the transcription of the E2F1 gene and its 
downstream targets. The importance of this function of hbz as a non-coding RNA is further reinforced 
by the recent finding of its localization mainly in the nucleus [62]. Interestingly, HTLV-1 does not 
encode a Vif ortholog, although a nucleocapsid portion of gag inhibits APOBEC3G restriction [100]. 
4. Expression Strategies of Other Human Complex Retroviruses 
Spumaviruses, also referred to as foamy viruses (FVs), have been isolated from several primate 
species,  cats,  cattle  and  horses,  and  a  few  other  mammals  [101].  The  first  FV  to  be  cloned  and 
sequenced was isolated from human cells [102] and is referred to as the prototype FV; it probably 
represented a zoonotic infection of a chimpanzee virus. Although FVs are highly cytopathic in many 
cell types in tissue culture, leading to syncytium formation, vacuolization and cell death [102], they do 
not appear to be pathogenic in vivo.  
Features that distinguish FVs from other complex retroviruses in terms of genetic organization, 
expression profile and replication strategy [103] include the use of a second plus-strand promoter in 
addition to the canonical LTR promoter, production of the Pol precursor protein from a spliced mRNA, 
and reliance on cellular factors rather than a Rev ortholog for nuclear export of incompletely spliced 
mRNAs [103]. 
The presence of 2 promoters permits a clear-cut temporal regulation of FV transcript expression. 
The internal promoter (IP) is located near the 3′end of the env gene and is responsible for expression of 
mRNAs coding for the regulatory/accessory proteins Tas (previously named Bel-1) and Bet [104]. 
Activity of both promoters is controlled by Tas, a strong transcriptional transactivator that binds to Viruses 2011, 3                                       
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specific DNA sequences [105]. Early in infection, basal activity of the IP results in low levels of Tas 
protein which in turn binds to regulatory regions of the IP, resulting in increased promoter activity and 
enhanced Tas production. Following the rise in Tas concentration, the protein drives expression from 
the LTR promoter [106]. This results in production of the unspliced genomic/Gag transcript and singly 
spliced transcript coding for Env as well as a singly spliced transcript coding for Pol [107–109].  
The  production  of  Pol  independently  of  Gag  may  lead  to  precocious  reverse  transcription;  this 
might explain another intriguing feature of FV, i.e., the production of virions which already contain 
proviral DNA genomes [110]. The role of Bet in FV replication is less well understood, although it has 
been shown to block APOBEC3 in some experimental systems [111,112].  
Early studies of FVs indicated that they do not rely on a viral post-transcriptional regulatory protein 
such as Rev for expression [113]. However, a recent study of the prototype  FV by Bodem et  al. 
demonstrated its reliance on the CRM1 export pathway for nuclear export of the unspliced transcript. 
This process is mediated through binding of the cellular protein HuR to an as yet-unidentified element 
on FV RNA, with the presence of HuR on the RNA allowing engagement of the CRM1 pathway 
through recruitment of the HuR-CRM1 bridging proteins ANP32A and ANP32B [114].  
Complex  genetic  structure  and  post-transcriptional  regulation  of  viral  gene  expression  are  also 
characteristic of some human endogenous retroviruses (HERVs). A subset of HERVs termed HERV-K 
entered  the  germline  of  primates  in  relatively  recent  times  (45  million  year  ago)  [115]  and  are 
considered to be the most active HERVs, as they are capable of expression and generating virus-like 
particles [116]. The HERV-Ks are divided in type 1 and type 2 proviruses depending on the absence or 
presence of a 292 nt sequence at the boundary between the pol and env genes; the absence of this 
region in type 1 proviruses results in fusion of pol and env. Type 2 HERV-Ks generate 4 transcripts of 
8.6 kb (full-length, encoding Gag-Pol), 3.3 kb (singly-spliced, encoding Env), 1.8 kb (doubly-spliced, 
encoding the Rec regulatory protein) and 1.5 kb (singly-spliced) [116]. Rec is a 14.7 kDa nucleolar 
protein that is functionally similar to HIV Rev and HTLV Rex. Rec function is mediated through its 
binding to a Rec Responsive Element (RcRE) located in the U3R segment of the 3' LTR. Similar to 
Rev  and  Rex,  Rec  enhances  stability  and  nuclear  export  of  the  unspliced  and  singly  spliced 
mRNAs [117]. Rec is expressed in normal testicular cells and at much higher levels in  germ  cell 
testicular  cancers.  Consistent  with  this  finding,  Rec  exhibits  oncogenic  properties  in  mice  [118]. 
Type 1 HERV-K proviruses, which do not express Rec, express Np9, a 9 kDa protein [119] that shares 
15 N-terminal  amino  acids  with  Rec  while  the  C-terminal  59  residues  are  encoded  in  a  different 
reading frame. It is noteworthy that most malignant tissues express Np9 while no Np9 transcripts are 
generated in normal human tissues. In the case of some tumors (e.g., breast cancer) expression of 
type 1 over type 2 HERV-K appears to be predominant [120].  
5. Open Questions and Perspectives 
Although considerable knowledge has been gained on the key features and regulatory mechanisms 
of retroviral gene expression, important questions remain to be addressed. 
The biological significance of HIV-1’s complex and apparently redundant splicing pattern remains 
to be understood. Furthermore, the relative abundance and the time course of expression have not been Viruses 2011, 3                                       
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measured at a single transcript level with quantitative splice-site-specific methods such as those used 
for studies of HTLV-1. 
Although the cellular machinery involved in Rex and Rev function appears to be similar, possible 
peculiarities are suggested by the nonreciprocal complementation of Rex and Rev function as well as 
by the positioning of the cis-acting responsive elements; while the HTLV-1 RXRE is present in all the 
positive strand viral mRNAs regardless of their Rex-dependence, in the case of HIV, the RRE element 
is present on the Rev-responsive transcripts and absent from the Rev-independent mRNAs. 
The mechanisms determining splice site selection in HTLV-1 and their possible connection with the 
differentiation and/or activation status of the host cell are largely unknown. The Rex-dependency of 
the alternatively spliced mRNAs encoding the accessory proteins (which do not contain any known 
cis-acting inhibitory elements) is not known at present. Furthermore, it is still unclear whether different 
patterns of viral gene expression/latency may lead to different clinical outcomes (no disease, ATLL or 
TSP/HAM). In addition it would be interesting to compare the levels and kinetics of mRNA expression 
of HTLV-1 to that of HTLV-2, a highly related deltaretrovirus with complex genetic organization and 
expression strategies. It would be most informative to carry out these studies using primary PBMCs 
from HTLV-2-infected patients, as the detection of a temporal switch in the expression of individual 
viral transcripts with splice site-specific Real Time RT-PCR has proven difficult to demonstrate in 
other systems [60,61]. 
Although  both  HTLV-1  and  HTLV-2  immortalize  T-cells  in  culture  and  establish  persistent 
infections  in  vivo,  the  2  viruses  exhibit  distinct  pathogenic  properties,  as  HTLV-2  has  not  been 
conclusively  linked  to  lymphoproliferative  or  neurodegenerative  diseases  [121].  Differences  in  the 
pattern and time course of expression of the two viruses could thus provide molecular grounds to 
explain their different pathobiology. 
The reliance of HIV on alternative splicing and its engagement of the Rev-CRM1 export pathway 
are already being exploited for the design of therapeutic agents that disrupt splicing or interfere with 
Rev function [17]. Given its similarities to HIV, similar strategies could be pursued for controlling 
HTLV-1 infection and pathogenesis. 
Acknowledgments 
We  thank  Luigi  Chieco-Bianchi  for  discussions.  This  work  was  supported  by  grants  from  
the  European  Union  (“The  role  of  chronic  infections  in  the  development  of  cancer,”  contract  
no.  2005-018704),  the  Associazione  Italiana  per  la  Ricerca  sul  Cancro  (AIRC),  the  Fondazione 
Cariverona, the Ministero per l’Università e la Ricerca Scientifica, e Tecnologica Progetti di Ricerca di 
Interesse  Nazionale  (PRIN),  the  Ministero  della  Salute  (project  RFPS-2006-2-342-010),  and  the 
University of Padova. 
Conflict of Interest 
The authors declare no conflict of interest.  Viruses 2011, 3                                       
 
 
1407
References and Notes 
1.  Goff, S.P. Retroviridae: The retroviruses and their replication. In Fields Virology, 5 ed.; Knipe, 
D.M., Howley, P.M., Eds.; Wolters Kluwer/Lippincott Williams and Wilkins: Philadelphia, PA, 
USA, 2007; Volume 2, pp. 1999–2070. 
2.  Cullen, B.R. Human immunodeficiency virus as a prototypic complex retrovirus. J. Virol. 1991, 
65, 1053–1056. 
3.  Mertz, J.A.; Simper, M.S.; Lozano, M.M.; Payne, S.M.; Dudley, J.P. Mouse mammary tumor 
virus encodes a self-regulatory RNA export protein and is a complex retrovirus. J. Virol. 2005, 79, 
14737–14747. 
4.  Indik,  S.;  Gunzburg,  W.H.;  Salmons,  B.;  Rouault,  F.  A  novel,  mouse  mammary  tumor  virus 
encoded protein with Rev-like properties. Virology 2005, 337, 1–6. 
5.  Lower, R.; Tonjes, R.R.; Korbmacher, C.; Kurth, R.; Lower, J. Identification of a Rev-related 
protein by analysis of spliced transcripts of the human endogenous retroviruses HTDV/HERV-K. 
J. Virol. 1995, 69, 141–149. 
6.  Pasquinelli, A.E.; Ernst, R.K.; Lund, E.; Grimm, C.; Zapp, M.L.; Rekosh, D.; Hammarskjold, 
M.L.; Dahlberg, J.E. The constitutive transport element (CTE) of Mason-Pfizer monkey virus 
(MPMV) accesses a cellular mRNA export pathway. EMBO J. 1997, 16, 7500–7510. 
7.  Young, L.S.; Rickinson, A.B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 2004, 4, 757–768. 
8.  Schwartz, S. HPV-16 RNA processing. Front. Biosci. 2008, 13, 5880–5891. 
9.  Moody, C.A.; Laimins, L.A. Human papillomavirus oncoproteins: Pathways to transformation. 
Nat. Rev. Cancer 2010, 10, 550–560. 
10.  Muesing, M.A.; Smith, D.H.; Cabradilla, C.D.; Benton, C.V.; Lasky, L.A.; Capon, D.J. Nucleic 
acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature 1985, 313, 
450–458. 
11.  Purcell, D.F.; Martin, M.A. Alternative splicing of human immunodeficiency virus type 1 mRNA 
modulates viral protein expression, replication, and infectivity. J. Virol. 1993, 67, 6365–6378. 
12.  Schwartz, S.; Felber, B.K.; Benko, D.M.; Fenyo, E.M.; Pavlakis, G.N. Cloning and functional 
analysis of multiply spliced mRNA species of human immunodeficiency virus type 1. J. Virol. 
1990, 64, 2519–2529. 
13.  Schwartz,  S.;  Felber,  B.K.;  Fenyo,  E.M.;  Pavlakis,  G.N.  Env  and  Vpu  proteins  of  human 
immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J. Virol. 1990, 64, 
5448–5456. 
14.  Schwartz, S.; Felber, B.K.; Pavlakis, G.N. Expression of human immunodeficiency virus type 1 
vif and vpr mRNAs is Rev-dependent and regulated by splicing. Virology 1991, 183, 677–686. 
15.  Briquet, S.; Vaquero, C. Immunolocalization studies of an antisense protein in HIV-1-infected 
cells and viral particles. Virology 2002, 292, 177–184. 
16.  Stoltzfus, C.M. Chapter 1. Regulation of HIV-1 alternative RNA splicing and its role in virus 
replication. Adv. Virus Res. 2009, 74, 1–40. 
17.  Tazi, J.; Bakkour, N.; Marchand, V.; Ayadi, L.; Aboufirassi, A.; Branlant, C. Alternative splicing: 
Regulation of HIV-1 multiplication as a target for therapeutic action. FEBS J. 2010, 277, 867–876. Viruses 2011, 3                                       
 
 
1408
18.  Brady, J.; Kashanchi, F. Tat gets the "green" light on transcription initiation. Retrovirology 2005, 
2, 69. 
19.  Landry, S.; Halin, M.; Lefort, S.; Audet, B.; Vaquero, C.; Mesnard, J.M.; Barbeau, B. Detection, 
characterization and regulation of antisense transcripts in HIV-1. Retrovirology 2007, 4, 71. 
20.  Berro, R.; Kehn, K.; de la Fuente, C.; Pumfery, A.; Adair, R.; Wade, J.; Colberg-Poley, A.M.; 
Hiscott, J.; Kashanchi, F. Acetylated Tat regulates human immunodeficiency virus type 1 splicing 
through its interaction with the splicing regulator p32. J. Virol. 2006, 80, 3189–3204. 
21.  Berro, R.; Pedati, C.; Kehn-Hall, K.; Wu, W.; Klase, Z.; Even, Y.; Geneviere, A.M.; Ammosova, 
T.; Nekhai, S.; Kashanchi, F. CDK13, a new potential human immunodeficiency virus type 1 
inhibitory factor regulating viral mRNA splicing. J. Virol. 2008, 82, 7155–7166. 
22.  Kammler, S.; Otte, M.; Hauber, I.; Kjems, J.; Hauber, J.; Schaal, H. The strength of the HIV-1 3' 
splice sites affects Rev function. Retrovirology 2006, 3, 89. 
23.  Cullen,  B.R.  Nuclear  mRNA  export:  Insights  from  virology.  Trends  Biochem.  Sci.  2003,  28,  
419–424. 
24.  Groom, H.C.; Anderson, E.C.; Lever, A.M. Rev: Beyond nuclear export. J. Gen. Virol. 2009, 90, 
1303–1318. 
25.  Rosen, C.A.; Terwilliger, E.; Dayton, A.; Sodroski, J.G.; Haseltine, W.A. Intragenic cis-acting art 
gene-responsive sequences of the human immunodeficiency virus. Proc. Natl. Acad. Sci. U. S. A. 
1988, 85, 2071–2075. 
26.  Maldarelli, F.; Martin, M.A.; Strebel, K. Identification of posttranscriptionally active inhibitory 
sequences  in  human  immunodeficiency  virus  type  1  RNA:  Novel  level  of  gene  regulation.  
J. Virol. 1991, 65, 5732–5743. 
27.  Nasioulas, G.; Zolotukhin, A.S.; Tabernero, C.; Solomin, L.; Cunningham, C.P.; Pavlakis, G.N.; 
Felber,  B.K.  Elements  distinct  from  human  immunodeficiency  virus  type  1  splice  sites  are 
responsible for the Rev dependence of env mRNA. J. Virol. 1994, 68, 2986–2993. 
28.  Schwartz, S.; Felber, B.K.; Pavlakis, G.N. Distinct RNA sequences in the gag region of human 
immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of 
Rev protein. J. Virol. 1992, 66, 150–159. 
29.  Fischer, U.; Meyer, S.; Teufel, M.; Heckel, C.; Luhrmann, R.; Rautmann, G. Evidence that HIV-1 
Rev directly promotes the nuclear export of unspliced RNA. EMBO J. 1994, 13, 4105–4112. 
30.  Schwartz, S.; Campbell, M.; Nasioulas, G.; Harrison, J.; Felber, B.K.; Pavlakis, G.N. Mutational 
inactivation  of  an  inhibitory  sequence  in  human  immunodeficiency  virus  type  1  results  in  
Rev-independent gag expression. J. Virol. 1992, 66, 7176–7182. 
31.  Berthold, E.; Maldarelli, F. cis-acting elements in human immunodeficiency virus type 1 RNAs 
direct viral transcripts to distinct intranuclear locations. J. Virol. 1996, 70, 4667–4682. 
32.  Kim, S.Y.; Byrn, R.; Groopman, J.; Baltimore, D. Temporal aspects of DNA and RNA synthesis 
during  human  immunodeficiency  virus  infection:  Evidence  for  differential  gene  expression. 
J. Virol. 1989, 63, 3708–3713. 
33.  Ahmad,  N.;  Maitra,  R.K.;  Venkatesan,  S.  Rev-induced  modulation  of  Nef  protein  underlies 
temporal regulation of human immunodeficiency virus replication. Proc. Natl. Acad. Sci. U. S. A. 
1989, 86, 6111–6115. Viruses 2011, 3                                       
 
 
1409
34.  Weinberger,  L.S.;  Burnett,  J.C.;  Toettcher,  J.E.;  Arkin,  A.P.;  Schaffer,  D.V.  Stochastic  gene 
expression  in  a  lentiviral  positive-feedback  loop:  HIV-1  Tat  fluctuations  drive  phenotypic 
diversity. Cell 2005, 122, 169–182. 
35.  Weinberger,  L.S.;  Dar,  R.D.;  Simpson,  M.L.  Transient-mediated  fate  determination  in  a 
transcriptional circuit of HIV. Nat. Genet. 2008, 40, 466–470. 
36.  Weinberger, L.S.; Shenk, T. An HIV feedback resistor: Auto-regulatory circuit deactivator and 
noise buffer. PLoS Biol. 2007, 5, e9. 
37.  Kirchhoff, F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate 
lentiviruses. Cell Host Microbe 2010, 8, 55–67. 
38.  Malim,  M.H.;  Emerman,  M.  HIV-1  accessory  proteins—Ensuring  viral  survival  in  a  hostile 
environment. Cell Host Microbe 2008, 3, 388–398. 
39.  Deacon, N.J.; Tsykin, A.; Solomon, A.; Smith, K.; Ludford-Menting, M.; Hooker, D.J.; McPhee, 
D.A.; Greenway, A.L.; Ellett, A.; Chatfield, C.; et al. Genomic structure of an attenuated quasi 
species of HIV-1 from a blood transfusion donor and recipients. Science 1995, 270, 988–991. 
40.  Lindwasser, O.W.; Chaudhuri, R.; Bonifacino, J.S. Mechanisms of CD4 downregulation by the 
Nef and Vpu proteins of primate immunodeficiency viruses. Curr. Mol. Med. 2007, 7, 171–184. 
41.  Lama, J.; Mangasarian, A.; Trono, D. Cell-surface expression of CD4 reduces HIV-1 infectivity 
by  blocking  Env  incorporation  in  a  Nef-  and  Vpu-inhibitable  manner.  Curr.  Biol.  1999,  9,  
622–631. 
42.  Ross, T.M.; Oran, A.E.; Cullen, B.R. Inhibition of HIV-1 progeny virion release by cell-surface 
CD4 is relieved by expression of the viral Nef protein. Curr. Biol. 1999, 9, 613–621. 
43.  Neil, S.J.; Zang, T.; Bieniasz, P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 
Vpu. Nature 2008, 451, 425–430. 
44.  Geleziunas,  R.;  Xu,  W.;  Takeda,  K.;  Ichijo,  H.;  Greene,  W.C.  HIV-1  Nef  inhibits  ASK1-
dependent death signalling providing a potential mechanism for protecting the infected host cell. 
Nature 2001, 410, 834–838. 
45.  Harris, R.S.; Liddament, M.T. Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 
2004, 4, 868–877. 
46.  Kogan, M.; Rappaport, J. HIV-1 accessory protein Vpr: Relevance in the pathogenesis of HIV and 
potential for therapeutic intervention. Retrovirology 2011, 8, 25. 
47.  Schoborg, R.V. Analysis of caprine arthritis encephalitis virus (CAEV) temporal gene expression 
in infected cells. Virus Res. 2002, 90, 37–46. 
48.  Sargan, D.R.; Roy, D.J.; Dalziel, R.G.; Watt, N.J.; McConnell, I. A temporal study of RNAs 
produced  in  maedi-visna  virus  infection  of  choroid  plexus  cells.  Vet.  Microbiol.  1994,  39,  
369–378. 
49.  Martarano, L.; Stephens, R.; Rice, N.; Derse, D. Equine infectious anemia virus trans-regulatory 
protein Rev controls viral mRNA stability, accumulation, and alternative splicing. J. Virol. 1994, 
68, 3102–3111. 
50.  Ciminale, V.; Pavlakis, G.N.; Derse, D.; Cunningham, C.P.; Felber, B.K. Complex splicing in the 
human  T-cell  leukemia  virus  (HTLV)  family  of  retroviruses:  Novel  mRNAs  and  proteins 
produced by HTLV type I. J. Virol. 1992, 66, 1737–1745. Viruses 2011, 3                                       
 
 
1410
51.  Koralnik, I.J.; Gessain, A.; Klotman, M.E.; Lo Monico, A.; Berneman, Z.N.; Franchini, G. Protein 
isoforms  encoded  by  the  pX  region  of  human  T-cell  leukemia/lymphotropic  virus  type  I. 
Proc. Natl. Acad. Sci. U. S. A. 1992, 89, 8813–8817. 
52.  Larocca, D.; Chao, L.A.; Seto, M.H.; Brunck, T.K. Human T-cell leukemia virus minus strand 
transcription in infected T-cells. Biochem. Biophys. Res. Commun. 1989, 163, 1006–1013. 
53.  Gaudray, G.; Gachon, F.; Basbous, J.; Biard-Piechaczyk, M.; Devaux, C.; Mesnard, J.M. The 
complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP 
transcription factor that down-regulates viral transcription. J. Virol. 2002, 76, 12813–12822. 
54.  Felber, B.K.; Paskalis, H.; Kleinman-Ewing, C.; Wong-Staal, F.; Pavlakis, G.N. The pX protein 
of HTLV-I is a transcriptional activator of its long terminal repeats. Science 1985, 229, 675–679. 
55.  Hidaka, M.;  Inoue, J.; Yoshida, M.; Seiki, M. Post-transcriptional regulator (rex) of HTLV-1 
initiates expression of viral structural proteins but suppresses expression of regulatory proteins. 
EMBO J. 1988, 7, 519–523. 
56.  Inoue, J.; Seiki, M.; Yoshida, M. The second pX product p27 chi-III of HTLV-1 is required for 
gag gene expression. FEBS Lett. 1986, 209, 187–190. 
57.  Bogerd, H.P.; Fridell, R.A.; Madore, S.; Cullen, B.R. Identification of a novel cellular cofactor for 
the Rev/Rex class of retroviral regulatory proteins. Cell 1995, 82, 485–494. 
58.  Hanly,  S.M.;  Rimsky,  L.T.;  Malim,  M.H.;  Kim,  J.H.;  Hauber,  J.;  Duc  Dodon,  M.;  Le,  S.Y.; 
Maizel, J.V.; Cullen, B.R.; Greene, W.C. Comparative analysis of the HTLV-I Rex and HIV-1 
Rev trans-regulatory proteins and their RNA response elements. Genes Dev. 1989, 3, 1534–1544. 
59.  Saiga,  A.;  Orita,  S.;  Minoura-Tada,  N.;  Maeda,  M.;  Aono,  Y.;  Asakawa,  M.;  Nakahara,  K.; 
Kubota, R.; Osame, M.; Igarashi, H. cis-Acting inhibitory elements within the pol-env region of 
human T-cell leukemia virus type 1 possibly involved in viral persistence. J. Virol. 1997, 71, 
4485–4494. 
60.  Li, M.; Green, P.L. Detection and quantitation of HTLV-1 and HTLV-2 mRNA species by real-
time RT-PCR. J. Virol. Meth. 2007, 142, 159–168. 
61.  Li, M.; Kesic, M.; Yin, H.; Yu, L.; Green, P.L. Kinetic analysis of human T-cell leukemia virus 
type 1 gene expression in cell culture and infected animals. J. Virol. 2009, 83, 3788–3797. 
62.  Rende, F.; Cavallari, I.; Corradin, A.; Silic-Benussi, M.; Toulza, F.; Toffolo, G.M.; Tanaka, Y.; 
Jacobson, S.; Taylor, G.P.; D'Agostino, D.M.; et al. Kinetics and intracellular compartmentalization 
of HTLV-1 gene expression: nuclear retention of HBZ mRNA. Blood 2011, doi:10.1182/blood-
2010-11-316463. 
63.  Corradin,  A.;  Di  Camillo,  B.;  Ciminale,  V.;  Toffolo,  G.;  Cobelli,  C.  Sensitivity  analysis  of 
retrovirus HTLV-1 transactivation. J. Comput. Biol. 2011, 18, 183–193. 
64.  Marriott, S.J.; Semmes, O.J. Impact of HTLV-I Tax on cell cycle progression and the cellular 
DNA damage repair response. Oncogene 2005, 24, 5986–5995. 
65.  Boxus, M.; Twizere, J.C.; Legros, S.; Dewulf, J.F.; Kettmann, R.; Willems, L. The HTLV-1 Tax 
interactome. Retrovirology 2008, 5, 76. 
66.  Saggioro, D.; Silic-Benussi, M.; Biasiotto, R.; D'Agostino, D.M.; Ciminale, V. Control of cell 
death pathways by HTLV-1 proteins. Front. Biosci. 2009, 14, 3338–3351. Viruses 2011, 3                                       
 
 
1411
67.  D'Agostino,  D.M.;  Ciminale,  V.;  Zotti,  L.;  Rosato,  A.;  Chieco-Bianchi,  L.  The  human  T-cell 
lymphotropic virus type 1 Tof protein contains a bipartite nuclear localization signal that is able to 
functionally replace the amino-terminal domain of Rex. J. Virol. 1997, 71, 75–83. 
68.  Nicot,  C.;  Dundr,  M.; Johnson,  J.M.;  Fullen, J.R.;  Alonzo,  N.;  Fukumoto,  R.; Princler,  G.L.; 
Derse, D.; Misteli, T.; Franchini, G. HTLV-1-encoded p30(II) is a post-transcriptional negative 
regulator of viral replication. Nat. Med. 2004, 10, 197–201. 
69.  Younis, I.; Khair, L.; Dundr, M.; Lairmore, M.D.; Franchini, G.; Green, P.L. Repression of human 
T-cell leukemia virus type 1 and type 2 replication by a viral mRNA-encoded posttranscriptional 
regulator. J. Virol. 2004, 78, 11077–11083. 
70.  Zhang, W.; Nisbet, J.W.; Albrecht, B.; Ding, W.; Kashanchi, F.; Bartoe, J.T.; Lairmore, M.D. 
Human  T-lymphotropic  virus  type  1  p30(II)  regulates  gene  transcription  by  binding  CREB 
binding protein/p300. J. Virol. 2001, 75, 9885–9895. 
71.  Zhang, W.; Nisbet, J.W.; Bartoe, J.T.; Ding, W.; Lairmore, M.D. Human T-lymphotropic virus 
type 1 p30(II) functions as a transcription factor and differentially modulates CREB-responsive 
promoters. J. Virol. 2000, 74, 11270–11277. 
72.  Michael, B.; Nair, A.M.; Hiraragi, H.; Shen, L.; Feuer, G.; Boris-Lawrie, K.; Lairmore, M.D. 
Human T lymphotropic virus type-1 p30II alters cellular gene expression to selectively enhance 
signaling pathways that activate T lymphocytes. Retrovirology 2004, 1, 39. 
73.  Taylor, J.M.; Ghorbel, S.; Nicot, C. Genome wide analysis of human genes transcriptionally and 
post-transcriptionally regulated by the HTLV-I protein p30. BMC Genomics 2009, 10, 311. 
74.  Sinha-Datta, U.; Datta, A.; Ghorbel, S.; Dodon, M.D.; Nicot, C. Human T-cell lymphotrophic 
virus type I rex and p30 interactions govern the switch between virus latency and replication. 
J. Biol. Chem. 2007, 282, 14608–14615. 
75.  Datta, A.; Sinha-Datta, U.; Dhillon, N.K.; Buch, S.; Nicot, C. The HTLV-I p30 interferes with 
TLR4 signaling and modulates the release of pro- and anti-inflammatory cytokines from human 
macrophages. J. Biol. Chem. 2006, 281, 23414–23424. 
76.  Heger, P.; Rosorius, O.; Hauber, J.; Stauber, R.H. Titration of cellular export factors, but not 
heteromultimerization,  is  the  molecular  mechanism  of  trans-dominant  HTLV-1  rex  mutants. 
Oncogene 1999, 18, 4080–4090. 
77.  Kubota, S.; Hatanaka, M.; Pomerantz, R.J. Nucleo-cytoplasmic redistribution of the HTLV-I Rex 
protein: Alterations by coexpression of the HTLV-I p21x protein. Virology 1996, 220, 502–507. 
78.  Ciminale, V.; Zotti, L.; D'Agostino, D.M.; Ferro, T.; Casareto, L.; Franchini, G.; Bernardi, P.; 
Chieco-Bianchi, L. Mitochondrial targeting of the p13II protein coded by the x-II ORF of human 
T-cell leukemia/lymphotropic virus type I (HTLV-I). Oncogene 1999, 18, 4505–4514. 
79.  D'Agostino,  D.M.; Silic-Benussi, M.; Hiraragi,  H.;  Lairmore, M.D.; Ciminale, V. The human  
T-cell leukemia virus type 1 p13II protein: effects on mitochondrial function and cell growth. Cell 
Death Differ. 2005, 12, 905–915. 
80.  Silic-Benussi,  M.;  Cavallari,  I.;  Zorzan,  T.;  Rossi,  E.;  Hiraragi,  H.;  Rosato,  A.;  Horie,  K.; 
Saggioro,  D.;  Lairmore,  M.D.;  Willems,  L.;  et  al.  Suppression  of  tumor  growth  and  cell 
proliferation by p13II, a mitochondrial protein of human T cell leukemia virus type 1. Proc. Natl. 
Acad. Sci. U. S. A. 2004, 101, 6629–6634. Viruses 2011, 3                                       
 
 
1412
81.  Hiraragi,  H.;  Michael,  B.;  Nair,  A.;  Silic-Benussi,  M.;  Ciminale,  V.;  Lairmore,  M.  Human  
T-lymphotropic virus type 1 mitochondrion-localizing protein p13II sensitizes Jurkat T cells to 
Ras-mediated apoptosis. J. Virol. 2005, 79, 9449–9457. 
82.  Silic-Benussi, M.; Cavallari, I.; Vajente, N.; Vidali, S.; Chieco-Bianchi, L.; Di Lisa, F.; Saggioro, 
D.; D'Agostino, D.M.; Ciminale, V. Redox regulation of T-cell turnover by the p13 protein of 
human T-cell leukemia virus type 1: Distinct effects in primary versus transformed cells. Blood 
2010, 116, 54–62. 
83.  Silic-Benussi, M.; Biasiotto, R.; Andresen, V.; Franchini, G.; D'Agostino, D.M.; Ciminale, V. 
HTLV-1 p13, a small protein with a busy agenda. Mol. Aspect. Med. 2010, 31, 350–358. 
84.  Andresen, V.; Pise-Masison, C.A.; Sinha-Datta, U.; Bellon, M.; Valeri, V.; Washington Parks, R.; 
Cecchinato,  V.;  Fukumoto,  R.;  Nicot,  C.;  Franchini,  G.  Suppression  of  HTLV-1  replication  
by  Tax-mediated  re-routing  of  the  p13  viral  protein  to  nuclear  speckles.  Blood  2011, 
doi:10.1182/blood-2010-06-293340. 
85.  Mulloy,  J.C.;  Crownley,  R.W.;  Fullen,  J.;  Leonard,  W.J.;  Franchini,  G.  The  human  T-cell 
leukemia/lymphotropic  virus  type  1  p12I  proteins  bind  the  interleukin-2  receptor  beta  and 
gammac chains and affects their expression on the cell surface. J. Virol. 1996, 70, 3599–3605. 
86.  Nicot, C.; Mulloy, J.C.; Ferrari, M.G.; Johnson, J.M.; Fu, K.; Fukumoto, R.; Trovato, R.; Fullen, 
J.; Leonard, W.J.; Franchini, G. HTLV-1 p12(I) protein enhances STAT5 activation and decreases 
the interleukin-2 requirement for proliferation of primary human peripheral blood mononuclear 
cells. Blood 2001, 98, 823–829. 
87.  Johnson,  J.M.;  Nicot,  C.;  Fullen,  J.;  Ciminale,  V.;  Casareto,  L.;  Mulloy,  J.C.;  Jacobson,  S.; 
Franchini, G. Free major histocompatibility complex class I heavy chain is preferentially targeted 
for degradation by  human T-cell leukemia/lymphotropic virus type 1 p12(I) protein. J. Virol. 
2001, 75, 6086–6094. 
88.  Ding, W.; Albrecht, B.; Luo, R.; Zhang, W.; Stanley, J.R.; Newbound, G.C.; Lairmore, M.D. 
Endoplasmic reticulum and cis-Golgi localization of human T-lymphotropic virus type 1 p12(I): 
Association with calreticulin and calnexin. J. Virol. 2001, 75, 7672–7682. 
89.  Ding, W.; Albrecht, B.; Kelley, R.E.; Muthusamy, N.; Kim, S.J.; Altschuld, R.A.; Lairmore, M.D. 
Human  T-cell  lymphotropic  virus  type  1  p12(I)  expression  increases  cytoplasmic  calcium  to 
enhance the activation of nuclear factor of activated T cells. J. Virol. 2002, 76, 10374–10382. 
90.  Albrecht,  B.;  D'Souza,  C.D.;  Ding,  W.;  Tridandapani,  S.;  Coggeshall,  K.M.;  Lairmore,  M.D. 
Activation of nuclear factor of activated T cells by human T-lymphotropic virus type 1 accessory 
protein p12(I). J. Virol. 2002, 76, 3493–3501. 
91.  Kim, S.J.; Ding, W.; Albrecht, B.; Green, P.L.; Lairmore, M.D. A conserved calcineurin-binding 
motif in human T lymphotropic virus type 1 p12I functions to modulate nuclear factor of activated 
T cell activation. J. Biol. Chem. 2003, 278, 15550–15557. 
92.  Nicot, C.; Harrod, R.L.; Ciminale, V.; Franchini, G. Human T-cell leukemia/lymphoma virus type 
1 nonstructural genes and their functions. Oncogene 2005, 24, 6026–6034. 
93.  Van Prooyen, N.; Andresen, V.; Gold, H.; Bialuk, I.; Pise-Masison, C.; Franchini, G. Hijacking 
the  T-cell  communication  network  by  the  human  T-cell  leukemia/lymphoma  virus  type  1  
(HTLV-1) p12 and p8 proteins. Mol. Aspect. Med. 2010, 31, 333–343. Viruses 2011, 3                                       
 
 
1413
94.  Van Prooyen, N.;  Gold, H.; Andresen, V.; Schwartz, O.; Jones, K.; Ruscetti, F.;  Lockett, S.; 
Gudla, P.; Venzon, D.; Franchini, G. Human T-cell leukemia virus type 1 p8 protein increases 
cellular conduits and virus transmission. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 20738–20743. 
95.  Xu,  W.;  Santini,  P.A.;  Sullivan,  J.S.;  He,  B.;  Shan,  M.;  Ball,  S.C.;  Dyer,  W.B.;  Ketas,  T.J.; 
Chadburn, A.; Cohen-Gould, L.; et al. HIV-1 evades virus-specific IgG2 and IgA responses by 
targeting systemic and intestinal B cells via long-range intercellular conduits. Nat. Immunol. 2009, 
10, 1008–1017. 
96.  Matsuoka, M.; Green, P.L. The HBZ gene, a key player in HTLV-1 pathogenesis. Retrovirology 
2009, 6, 71. 
97.  Clerc, I.; Polakowski, N.; Andre-Arpin, C.; Cook, P.; Barbeau, B.; Mesnard, J.M.; Lemasson, I. 
An interaction between the human T cell leukemia virus type 1 basic leucine zipper factor (HBZ) 
and  the  KIX  domain  of  p300/CBP  contributes  to  the  down-regulation  of  tax-dependent  viral 
transcription by HBZ. J. Biol. Chem. 2008, 283, 23903–23913. 
98.  Arnold, J.; Zimmerman, B.; Li, M.; Lairmore, M.D.; Green, P.L. Human T-cell leukemia virus 
type-1  antisense-encoded  gene,  Hbz,  promotes  T-lymphocyte  proliferation.  Blood  2008,  112, 
3788–3797. 
99.  Satou, Y.; Yasunaga, J.; Yoshida, M.; Matsuoka, M. HTLV-I basic leucine zipper factor gene 
mRNA supports proliferation of adult T cell leukemia cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 
103, 720–725. 
100. Derse, D.; Hill, S.A.; Princler, G.; Lloyd, P.; Heidecker, G. Resistance of human T cell leukemia 
virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid. Proc. Natl. Acad. 
Sci. U. S. A. 2007, 104, 2915–2920. 
101. Linial, M. Foamy viruses. In Fields Virology, 5th ed.; Knipe, D., Howley, P., Eds.; Lippincott 
Williams and Wilkins: Philadelphia, PA, USA, 2007; Volume 2, pp. 2245–2262. 
102. Linial, M.L. Foamy viruses are unconventional retroviruses. J. Virol. 1999, 73, 1747–1755. 
103. Rethwilm,  A.  Molecular  biology  of  foamy  viruses.  Med.  Microbiol.  Immunol.  2010,  199,  
197–207. 
104. Lochelt,  M.;  Flugel,  R.M.;  Aboud,  M.  The  human  foamy  virus  internal  promoter  directs  the 
expression of the functional Bel 1 transactivator and Bet protein early after infection. J. Virol. 
1994, 68, 638–645. 
105. Keller, A.; Partin, K.M.; Lochelt, M.; Bannert, H.; Flugel, R.M.; Cullen, B.R. Characterization of 
the transcriptional trans activator of human foamy retrovirus. J. Virol. 1991, 65, 2589–2594. 
106. Meiering, C.D.; Rubio, C.; May, C.; Linial, M.L. Cell-type-specific regulation of the two foamy 
virus promoters. J. Virol. 2001, 75, 6547–6557. 
107. Jordan, I.; Enssle, J.; Guttler, E.; Mauer, B.; Rethwilm, A. Expression of human foamy virus 
reverse transcriptase involves a spliced pol mRNA. Virology 1996, 224, 314–319. 
108. Bodem, J.; Lochelt, M.; Winkler, I.; Flower, R.P.; Delius, H.; Flugel, R.M. Characterization of the 
spliced pol transcript of feline foamy virus: The splice acceptor site of the pol transcript is located 
in gag of foamy viruses. J. Virol. 1996, 70, 9024–9027. 
109. Yu, S.F.; Edelmann, K.; Strong, R.K.; Moebes, A.; Rethwilm, A.; Linial, M.L. The carboxyl 
terminus  of  the  human  foamy  virus  Gag  protein  contains  separable  nucleic  acid  binding  and 
nuclear transport domains. J. Virol. 1996, 70, 8255–8262. Viruses 2011, 3                                       
 
 
1414
110. Yu, S.F.; Sullivan, M.D.; Linial, M.L. Evidence that the human foamy virus genome is DNA. 
J. Virol. 1999, 73, 1565–1572. 
111. Russell, R.A.; Wiegand, H.L.; Moore, M.D.; Schafer, A.; McClure, M.O.; Cullen, B.R. Foamy 
virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral 
defense factors. J. Virol. 2005, 79, 8724–8731. 
112. Lochelt,  M.;  Romen,  F.;  Bastone,  P.;  Muckenfuss,  H.;  Kirchner,  N.;  Kim,  Y.B.;  Truyen,  U.; 
Rosler, U.; Battenberg, M.; Saib, A.; et al. The antiretroviral activity of APOBEC3 is inhibited by 
the foamy virus accessory Bet protein. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 7982–7987. 
113. Lee, A.H.; Lee, H.Y.; Sung, Y.C. The gene expression of human foamy virus does not require a 
post-transcriptional transactivator. Virology 1994, 204, 409–413. 
114. Bodem,  J.;  Schied,  T.;  Gabriel,  R.;  Rammling,  M.;  Rethwilm,  A.  Foamy  virus  nuclear  RNA 
export is distinct from that of other retroviruses. J. Virol. 2011, 85, 2333–2341. 
115. Turner,  G.;  Barbulescu,  M.;  Su,  M.;  Jensen-Seaman,  M.I.;  Kidd,  K.K.;  Lenz,  J.  Insertional 
polymorphisms of full-length endogenous retroviruses in humans. Curr. Biol. 2001, 11, 1531–1535. 
116. Bannert,  N.;  Kurth,  R.  Retroelements  and  the  human  genome:  New  perspectives  on  an  old 
relation. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 14572–14579. 
117. Magin, C.; Lower, R.; Lower, J. cORF and RcRE, the Rev/Rex and RRE/RxRE homologues of 
the human endogenous retrovirus family HTDV/HERV-K. J. Virol. 1999, 73, 9496–9507. 
118. Boese,  A.;  Sauter,  M.;  Galli,  U.;  Best,  B.;  Herbst,  H.;  Mayer,  J.;  Kremmer,  E.;  Roemer,  K.; 
Mueller-Lantzsch, N. Human endogenous retrovirus protein cORF supports cell transformation and 
associates with the promyelocytic leukemia zinc finger protein. Oncogene 2000, 19, 4328–4336. 
119. Armbruester, V.; Sauter, M.; Krautkraemer, E.; Meese, E.; Kleiman, A.; Best, B.; Roemer, K.; 
Mueller-Lantzsch,  N.  A  novel  gene  from  the  human  endogenous  retrovirus  K  expressed  in 
transformed cells. Clin. Cancer Res. 2002, 8, 1800–1807. 
120. Wang-Johanning, F.; Frost, A.R.; Johanning, G.L.; Khazaeli, M.B.; LoBuglio, A.F.; Shaw, D.R.; 
Strong, T.V. Expression of human endogenous retrovirus k envelope transcripts in human breast 
cancer. Clin. Cancer Res. 2001, 7, 1553–1560. 
121. Lairmore, M.; Franchini, G. Human T-cell leukemia virus types 1 and  2.  In Fields Virology, 
5th ed.; Knipe, D., Howley, P., Eds.; Lippincott Williams and Wilkins: Philadelphia, PA, USA, 
2007; Volume 2, pp. 2071–2106. 
©  2011  by  the  authors;  licensee  MDPI,  Basel,  Switzerland.  This  article  is  an  open  access  article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 